KR101855242B1 - 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 - Google Patents

펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 Download PDF

Info

Publication number
KR101855242B1
KR101855242B1 KR1020147023782A KR20147023782A KR101855242B1 KR 101855242 B1 KR101855242 B1 KR 101855242B1 KR 1020147023782 A KR1020147023782 A KR 1020147023782A KR 20147023782 A KR20147023782 A KR 20147023782A KR 101855242 B1 KR101855242 B1 KR 101855242B1
Authority
KR
South Korea
Prior art keywords
ala
leu
cys
thr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147023782A
Other languages
English (en)
Korean (ko)
Other versions
KR20140132342A (ko
Inventor
크리스토퍼 제이. 소레스
Original Assignee
크리스토퍼 제이. 소레스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스토퍼 제이. 소레스 filed Critical 크리스토퍼 제이. 소레스
Publication of KR20140132342A publication Critical patent/KR20140132342A/ko
Application granted granted Critical
Publication of KR101855242B1 publication Critical patent/KR101855242B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020147023782A 2012-01-26 2013-01-25 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 Active KR101855242B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591236P 2012-01-26 2012-01-26
US61/591,236 2012-01-26
PCT/US2013/023260 WO2013112912A1 (en) 2012-01-26 2013-01-25 Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177016079A Division KR102052983B1 (ko) 2012-01-26 2013-01-25 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20140132342A KR20140132342A (ko) 2014-11-17
KR101855242B1 true KR101855242B1 (ko) 2018-05-09

Family

ID=47682066

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147023782A Active KR101855242B1 (ko) 2012-01-26 2013-01-25 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
KR1020177016079A Active KR102052983B1 (ko) 2012-01-26 2013-01-25 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177016079A Active KR102052983B1 (ko) 2012-01-26 2013-01-25 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도

Country Status (14)

Country Link
US (3) US9193776B2 (enExample)
EP (2) EP2807187B1 (enExample)
JP (3) JP6025871B2 (enExample)
KR (2) KR101855242B1 (enExample)
CN (2) CN104271596B (enExample)
AU (2) AU2013211929B2 (enExample)
CA (1) CA2861392C (enExample)
DK (1) DK2807187T3 (enExample)
ES (2) ES2819825T3 (enExample)
IL (2) IL233655A (enExample)
MX (1) MX347229B (enExample)
NO (1) NO2864579T3 (enExample)
RU (2) RU2624016C2 (enExample)
WO (1) WO2013112912A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2807187B1 (en) * 2012-01-26 2017-07-26 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
EP3027644B1 (en) 2013-07-30 2019-08-21 Christopher J. Soares Cgrp agonist peptides
JO3669B1 (ar) * 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
US11034745B2 (en) * 2016-01-04 2021-06-15 Adepthera Llc Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones
JP7123932B2 (ja) * 2016-09-02 2022-08-23 クリストファー ジェイ． ソアレス 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用
CA2967616A1 (en) * 2016-09-19 2018-03-19 The Governors Of The University Of Alberta Brain penetrant amylin receptor based peptides for alzheimer's disease
US20200353088A1 (en) * 2017-11-06 2020-11-12 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
JP7214104B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4530838A (en) 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
JPS62231168A (ja) 1986-03-21 1987-10-09 ハイブリテツク・インコ−ポレイテツド アナライト−レセプタ−分析用内部標準を設けるための改良法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1994021665A1 (en) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
US7812120B2 (en) 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
CN101208098A (zh) * 2005-03-31 2008-06-25 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
KR20080003849A (ko) * 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
AU2006312307A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
SI3045182T1 (en) * 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
EP2219664A1 (en) 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
WO2013059336A1 (en) 2011-10-18 2013-04-25 Amylin Pharmaceuticals, Llc Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
EP2807187B1 (en) * 2012-01-26 2017-07-26 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
RS56556B1 (sr) 2012-02-27 2018-02-28 Bristol Myers Squibb Co N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, Vol.46(12):2427-2435 (2003. 06. 05.)
Journal of Pharmacology and Experimental Therapeutics, Vol.319(2):749-747 (2006. 11. 01.)

Also Published As

Publication number Publication date
RU2014131605A (ru) 2016-03-20
RU2017119773A3 (enExample) 2020-11-18
WO2013112912A1 (en) 2013-08-01
RU2017119773A (ru) 2018-12-06
JP6411425B2 (ja) 2018-10-24
AU2013211929B2 (en) 2016-05-26
EP3272769A1 (en) 2018-01-24
RU2624016C2 (ru) 2017-06-30
JP6025871B2 (ja) 2016-11-16
KR20140132342A (ko) 2014-11-17
HK1249915A1 (en) 2018-11-16
JP2017036308A (ja) 2017-02-16
JP2015513318A (ja) 2015-05-07
HK1201068A1 (en) 2015-08-21
US20140329752A1 (en) 2014-11-06
US10370425B2 (en) 2019-08-06
JP2019006821A (ja) 2019-01-17
CN104271596B (zh) 2018-09-18
ES2641325T3 (es) 2017-11-08
AU2013211929A1 (en) 2014-09-11
CA2861392A1 (en) 2013-08-01
IL233655A (en) 2017-06-29
IL252555A0 (en) 2017-07-31
KR102052983B1 (ko) 2019-12-06
EP3272769B1 (en) 2020-06-17
US9193776B2 (en) 2015-11-24
IL252555B (en) 2020-06-30
US20160145315A1 (en) 2016-05-26
EP2807187A1 (en) 2014-12-03
CN104271596A (zh) 2015-01-07
AU2016205801A1 (en) 2016-08-04
DK2807187T3 (en) 2017-09-11
CN108997490A (zh) 2018-12-14
MX347229B (es) 2017-04-19
RU2742826C2 (ru) 2021-02-11
ES2819825T3 (es) 2021-04-19
NO2864579T3 (enExample) 2018-01-20
IL233655A0 (en) 2014-08-31
KR20170071613A (ko) 2017-06-23
MX2014008960A (es) 2015-01-16
EP2807187B1 (en) 2017-07-26
CA2861392C (en) 2021-08-17
BR112014018284A2 (pt) 2017-07-04
US20170204155A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
KR102052983B1 (ko) 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
WO2009034119A1 (en) Improved derivatives of amylin
EP0672054A1 (en) A novel molecule which inhibits neuropeptide tyrosine biological function
KR20010085847A (ko) 펩티드 유도체
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
JP2019504119A (ja) ペプチド類似体
EP3027644B1 (en) Cgrp agonist peptides
HK1249915B (en) Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
HK1201068B (en) Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
JP4760377B2 (ja) ＧＰＲ１０３−ｌｉｋｅ受容体蛋白質に対するリガンドの新規用途
BR112014018284B1 (pt) Antagonista de peptídeo relacionado ao gene da calcitonina, composições farmacêuticas e uso dos mesmos
AU3250693A (en) A novel molecule which inhibits neuropeptide tyrosine biological function

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20210329

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20220323

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9